CIK 0001662774
- Non-accelerated filer
- Smaller reporting company
IRulya Therapeutics Inc.
Sign in to watch- Ticker
- IRLA
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 901024039
- Phone
- +1 203-208-8994
- Business address
- 101 COLLEGE STREET, SUITE 210, NEW HAVEN, CT, 06510
- Former names
- Quince Therapeutics, Inc., Cortexyme, Inc.
- 4 Open-market buy Director bought 67,881 shares at an average $1.02 ($69,233)
- 4 Open-market buy Director bought 57,369 shares at an average $1.01 ($58,134)
- 4 Open-market buy Director bought 43,134 shares at an average $0.94 ($40,546)
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 3 Insider Initial Statement of Ownership
- 4 Derivatives Options or other derivatives
- 3 Insider Initial Statement of Ownership
- 4 Derivatives Options or other derivatives
- 3 Insider Initial Statement of Ownership
- 4 Open-market buy Director bought 82,052 shares at an average $1.32 ($107,898)
- 4 Open-market buy Director bought 250,000 shares at an average $1.30 ($325,737)
- 4 Open-market buy Chief Executive Officer bought 88,000 shares at $1.26 ($110,880)
- 4 Open-market buy Chief Executive Officer bought 80,000 shares at $1.24 ($99,200)
- 4 Open-market buy Chief Business Officer bought 71,762 shares at $1.22 ($87,550)
- 4 Open-market buy Director bought 8,000 shares at $1.23 ($9,840)
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
Page 4 of 11 · 211 filings